[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE047272T2 - Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére - Google Patents

Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére

Info

Publication number
HUE047272T2
HUE047272T2 HUE16786583A HUE16786583A HUE047272T2 HU E047272 T2 HUE047272 T2 HU E047272T2 HU E16786583 A HUE16786583 A HU E16786583A HU E16786583 A HUE16786583 A HU E16786583A HU E047272 T2 HUE047272 T2 HU E047272T2
Authority
HU
Hungary
Prior art keywords
treating
pharmaceutical composition
preventing cancer
cancer
preventing
Prior art date
Application number
HUE16786583A
Other languages
English (en)
Inventor
Akira Kurihara
Hyongi CHON
Takayuki Fujita
Fumiyoshi Okano
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of HUE047272T2 publication Critical patent/HUE047272T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K4/00Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16786583A 2015-04-30 2016-04-28 Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére HUE047272T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015093640 2015-04-30

Publications (1)

Publication Number Publication Date
HUE047272T2 true HUE047272T2 (hu) 2020-04-28

Family

ID=57198482

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16786583A HUE047272T2 (hu) 2015-04-30 2016-04-28 Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére

Country Status (15)

Country Link
US (1) US11129893B2 (hu)
EP (1) EP3290051B1 (hu)
JP (1) JP6862828B2 (hu)
CN (1) CN107530426A (hu)
AU (1) AU2016255255B2 (hu)
BR (1) BR112017022390A2 (hu)
CA (1) CA2983232A1 (hu)
DK (1) DK3290051T3 (hu)
ES (1) ES2762979T3 (hu)
HU (1) HUE047272T2 (hu)
MX (1) MX2017013480A (hu)
PL (1) PL3290051T3 (hu)
PT (1) PT3290051T (hu)
RU (1) RU2714205C2 (hu)
WO (1) WO2016175307A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019295277A1 (en) * 2018-06-26 2021-01-21 Kagoshima University Antibody binding to chondroitin sulfate proteoglycan-5
US11873337B2 (en) 2018-06-26 2024-01-16 Kyowa Kirin Co., Ltd. Antibody binding to cell adhesion molecule 3
CN111073889B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人cspg5基因的用途及相关产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
JP4315257B2 (ja) 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするdnaおよびそれに対する抗体
JPH09194502A (ja) * 1995-11-13 1997-07-29 Seikagaku Kogyo Co Ltd 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするdnaおよびそれに対する抗体
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CN101245386A (zh) * 2008-03-26 2008-08-20 中南大学 用于多种肿瘤抑瘤基因检测的cDNA芯片
BRPI0910509B8 (pt) 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
KR101667319B1 (ko) * 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
EP2452950B1 (en) * 2009-07-08 2017-11-15 ACTGen, Inc. Anti-podxl2 antibody having anti-cancer activity
JP2013013327A (ja) * 2009-10-29 2013-01-24 Actgen Inc Mansc1蛋白質に結合し、抗癌活性を有する抗体
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途

Also Published As

Publication number Publication date
BR112017022390A2 (pt) 2018-10-23
RU2017135005A3 (hu) 2019-09-04
JPWO2016175307A1 (ja) 2018-02-22
PL3290051T3 (pl) 2020-04-30
DK3290051T3 (da) 2020-01-06
JP6862828B2 (ja) 2021-04-21
EP3290051B1 (en) 2019-10-23
US11129893B2 (en) 2021-09-28
KR20170141660A (ko) 2017-12-26
MX2017013480A (es) 2017-12-07
AU2016255255B2 (en) 2021-07-22
RU2017135005A (ru) 2019-04-08
US20180085453A1 (en) 2018-03-29
AU2016255255A1 (en) 2017-11-02
CN107530426A (zh) 2018-01-02
EP3290051A1 (en) 2018-03-07
ES2762979T3 (es) 2020-05-26
PT3290051T (pt) 2020-01-07
WO2016175307A1 (ja) 2016-11-03
RU2714205C2 (ru) 2020-02-13
CA2983232A1 (en) 2016-11-03
EP3290051A4 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
IL304820A (en) Preparations and methods for the treatment of cancer
PT3431105T (pt) Composição medicinal para tratamento de cancro
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
PT3377516T (pt) Composição para o tratamento do cancro
EP3533466A4 (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
IL256523A (en) Compositions and methods for treating cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL268416A (en) Pharmaceutical combinations for cancer treatment
EP3708173C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING MIRNA-3140 FOR THE TREATMENT OF CANCER
PL3129378T3 (pl) Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL255638A (en) Compositions and methods for treating cancer
HK1232128A1 (zh) 用於預防或治療皮疹的藥物組合物
HUE047272T2 (hu) Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
ZA201802268B (en) Methods and compositions for preventing or treating cancer
EP3563856A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF
EP3372233A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
PL3236961T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
GB201519644D0 (en) Therapy and pharmaceutical composition
ZA201904626B (en) Cancer treatment method and composition
HK1250958A1 (zh) 用於治療癌症的組合物和方法
IL255541A (en) Cabazitaxel and its use for treating cancer
EP3388067A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP3498284A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING AND / OR PREVENTING CANCER